

1 **TITLE PAGE**

2 **Manuscript Title:** Awareness and use of Tranexamic Acid in the management of  
3 Postpartum Haemorrhage among health care providers in Enugu, Nigeria.

4  
5 **Authors:** Ogochukwu Onwujekwe<sup>1</sup>, Adaobi Uchenna Mosanya<sup>2\*</sup>, Kingsley Ekwuazi<sup>3</sup>,  
6 Chukwuemeka Iyoke<sup>4</sup>.

- 7  
8 1. Department of Pharmacy, University of Nigeria Teaching Hospital, Enugu, Nigeria  
9 2. Department of Clinical Pharmacy and Pharmacy Management, University of Nigeria, Nsukka.  
10 3. Department of Obstetrics and Gynaecology, University of Nigeria Teaching Hospital, Enugu,  
11 Nigeria.  
12 4. Department of Obstetrics and Gynaecology, University of Nigeria Teaching Hospital, Enugu,  
13 Nigeria.

14  
15 **\*Corresponding author:** Adaobi Uchenna Mosanya, Department of Clinical Pharmacy and Pharmacy  
16 Management, University of Nigeria, Nsukka.

17 **Faculty of Pharmaceutical Sciences building, Chime Avenue, University of Nigeria, Nsukka, Enugu**  
18 **State, Nigeria. P.M.B. 410001**

19 [adaobi.mosanya@unn.edu.ng](mailto:adaobi.mosanya@unn.edu.ng) Tel: +234 8054 570 666  
20  
21  
22  
23  
24

25

## ABSTRACT

26 **Objectives:** This study was carried out to determine the knowledge, practice and barriers  
27 regarding the use of Tranexamic acid for the prevention and treatment of postpartum  
28 hemorrhage among health care providers in Enugu, Nigeria.

29 **Methods:** A cross sectional study was carried out among health professionals (Doctors,  
30 Pharmacists and Nurses) in two Nigerian tertiary teaching hospitals. One is Federal and  
31 the other is State. A total of 220 questionnaires were distributed, 207 were collected back  
32 (response rate: 94%) and analyzed using SPSS for inferential statistics with level of  
33 significance at  $p < 0.05$ .

34 **Results:** Only 23.7% of the respondents had good Knowledge ( $p < 0.001$ ). Good  
35 awareness of the recent WHO recommendation on the use of Tranexamic acid for  
36 Postpartum Haemorrhage was low (19.8%,  $< 0.001$ ). Majority of the respondents have  
37 neither prescribed nor dispensed it (30%;  $< 0.001$ ). Very few respondents use it for all  
38 cases of Postpartum Haemorrhage (16.4%;  $p < 0.001$ ). Barriers against its use include  
39 non-awareness of the latest WHO recommendation, preference for other utero-tonics  
40 and cost of the drug.

41 **Conclusions:** There was poor knowledge of Tranexamic acid, poor awareness of its  
42 recommendation and low use for Postpartum Haemorrhage among different cadres of  
43 health care providers.

44 **Keywords:** Postpartum haemorrhage; Tranexamic acid; Maternal mortality; WHO;  
45 Nigeria.

46 **Synopsis:** There was poor knowledge of Tranexamic acid, poor awareness of its  
47 recommendation and low use for Postpartum Haemorrhage among different cadres of  
48 health care providers.

## 49 **Introduction**

50 Maternal mortality is a major public health issue and maternal related causes accounted  
51 for 10.7 million deaths 1990 and 2015<sup>1</sup> . Globally an estimate of 303,000 maternal deaths  
52 occurred in 2015 mostly in the low resource settings, and most of them could have been  
53 prevented <sup>1</sup> Nigeria has one of the highest ratios of maternal mortality in the world  
54 accounting for approximately 58,000 maternal deaths i.e. 19% globally <sup>1</sup> . One out of five  
55 causes of 70% of maternal mortality in Nigeria is hemorrhage <sup>2</sup> In April,2016, The World  
56 Maternal Antifibrinolytic trial (WOMAN) showed that showed Tranexamic acid when given  
57 early to women with Postpartum Haemorrhage could prevent one in three women from  
58 dying <sup>3</sup> . As a consequence, the World Health Organization (WHO) published an updated  
59 recommendation on the use of Tranexamic acid (TXA) for Postpartum Haemorrhage  
60 treatment <sup>4</sup> . Since then, several studies have been done to evaluate the safety and  
61 effectiveness (including cost-effectiveness) of Tranexamic acid for the prevention and  
62 treatment of postpartum hemorrhage, which may occur after vaginal as well as cesarean  
63 deliveries <sup>5-14</sup>

64 Currently, there is no published study on the awareness of health care professionals  
65 regarding the use of Tranexamic acid for the prevention and management of Postpartum  
66 Haemorrhage in Nigeria. Therefore, this study aimed to determine the knowledge and  
67 practice of health care providers in Enugu Metropolis on the use of Tranexamic acid for  
68 the management of Postpartum Haemorrhage and the barriers to effective adoption and  
69 implementation of the new recommendation. The findings of the work is expected to have  
70 important implications for the delivery of high quality maternal care and prevention of  
71 maternal death through Postpartum Haemorrhage.

## 72 **METHODS**

### 73 **Study design**

74 The study was a cross sectional study and data were collected using a structured pre  
75 tested questionnaire for health providers involved in obstetrics and Gynecology in both  
76 hospitals. The respondents were medical doctors, nurses and pharmacists. A  
77 consecutive sampling method was used in administering the questionnaires.

### 78 **Study setting**

79 The study was carried out in Enugu metropolis. Enugu is the capital city of Enugu State.  
80 There are two tertiary public hospitals and several private hospitals (three of which are  
81 faith based). The inhabitants of Enugu are mostly civil servants, although the city is  
82 increasingly acquiring commercial activities. The population is comprised of mostly  
83 people who are mainly Igbo by tribe and Christian by religion. The study was carried out  
84 in Enugu State which has two tertiary teaching hospitals with Obstetrics and  
85 Gynaecology units. Each of these centres records about 1000-3000 deliveries per  
86 annum. The study population comprised of healthcare providers (doctors, Pharmacists  
87 and nurses) working with the Obstetrics and Gynaecology units.

### 88 **Sampling method**

89 A convenient sample of 220 questionnaires was administered to the respondents. A  
90 proportionate allocation was used to get the sample of respondents in the two hospitals  
91 based on the population of appropriate healthcare providers in both hospitals. Hence,  
92 145 was allocated to the Federal teaching hospital while 75 was to the State teaching  
93 hospital.

94

95

## 96 **Data collection instrument**

97 A pre-tested structured questionnaire was used to collect data. The questionnaire was  
98 divided into 5 sections, the first section was on the Social demographic characteristics,  
99 the second was on Awareness and knowledge of respondents on the use of Tranexamic  
100 acid for Postpartum Haemorrhage (PPH) treatment and prevention, the third section was  
101 on provider practices, the fourth section was on the use of Tranexamic acid for  
102 Postpartum Haemorrhage and the last section was on acceptability and barriers to use of  
103 Tranexamic acid for Postpartum Haemorrhage.

104

## 105 **Data collection and analysis**

106 Copies of the questionnaire were distributed to the respondents by the researcher after a  
107 brief introduction of the research work, the purpose of the study and obtaining verbal  
108 consent from the prospective participants. Data collection began towards the end of  
109 2019. However, it was interrupted by COVID-19 pandemic and the subsequent  
110 lockdown. It was finally concluded in 2021. Data was analyzed using Statistical Package  
111 for Social Sciences (SPSS) version 25 and Microsoft Excel 2019. The results from the  
112 data analysis were presented using descriptive and inferential statistics. Frequencies and  
113 percentages were used to summarize the items on the various sections of the  
114 questionnaire.

115

## 116 **Outcome measurement**

117 An overall knowledge/Awareness, Practice and Use was determined by scoring each  
118 correct response made by the respondents and summed them up to get the total score.  
119 The score was categorized as good if (> 50%) and poor (<50%). The inferential statistics

120 –the Chi square Test of significance was used to assess the relationship between  
121 knowledge of Tranexamic acid and professions, institutions as well as the relationship  
122 between the use of Tranexamic acid and professions, institutions. The relationship was  
123 termed significant if p-value is less than .05 ( $p < .05$ ).

124

### 125 **Ethical Consideration**

126 Ethical clearance was obtained from the ethical committee of the University of Nigeria  
127 Teaching Hospital and informed consent was obtained from all respondents before  
128 completing the questionnaire and those that declined were left out.

129

### 130 **RESULTS.**

131 A total of 207 questionnaires were returned and analyzed. This comprised of seventy  
132 (70) respondents (response rate: 93.33%) from the Enugu state university teaching  
133 hospital and one hundred and thirty seven (137) respondents (response rate: 94.48%)  
134 from the University of Nigeria Teaching Hospital Ituku Ozalla, Enugu State.

135

### 136 **Socio Demographic Characteristics**

137 Approximately half (51.7%) of the respondents were medical doctors, 46.4 % were within  
138 the ages 30-39 years, while 57% were females (Table 1) Regarding their cadre, the  
139 doctors were mainly house officers (48.6%) while the pharmacists were mainly interns  
140 (29.5%) and the nurses were majorly staff nurses/midwives (56.4%). A greater  
141 percentage of the participants had bachelor's degree as their highest education level  
142 (67.6%) and those with less than 5 years of practice accounted for 39.6%.

143

144 **Knowledge on the Use of Tranexamic Acid for postpartum hemorrhage**

145 A good proportion of the respondents (85.5%) knew that post-partum haemorrhage  
146 associated deaths could be avoided by the use of prophylactic uterotonics during the  
147 third stage of labor (Table 2). However, very few (14%) knew that the conclusion of the  
148 Guideline Development Group meeting on the prevention and treatment of post-partum  
149 haemorrhage in March 2012 was that there was no direct evidence of the effectiveness  
150 and safety of tranexamic acid for post- partum haemorrhage. Knowledge of tranexamic  
151 acid as a synthetic lysine analog trans-4 aminoethylcyclo hexanecarboxylic acid was  
152 about average (50.2%); those who knew that the mechanism of action of tranexamic acid  
153 was by binding to plasminogen molecules, thereby blocking the binding of lysine to them  
154 were almost average (45.9%). In summary, the proportion of the respondents with good  
155 knowledge regarding the use of Tranexamic acid for Postpartum Haemorrhage was very  
156 low (Table 3)

157

158 **Provider Practices of Tranexamic acid for postpartum hemorrhage**

159 Some of the providers (28%) perceived that tranexamic acid should be used in all cases  
160 of post-partum haemorrhage regardless of if bleeding is due to genital tract trauma or  
161 other causes (Table 4). However, majority believed that tranexamic acid should be  
162 recognized as a life-saving intervention and made readily available for the management  
163 of Postpartum Haemorrhage in settings where obstetric care is provided (67.1%).

164

165 **Attitude on the use of Tranexamic acid for postpartum hemorrhage**

166 Approximately a quarter of the respondents (21.7%) indicated the recommended dosage  
167 regimen of 1g (100mg/ml) IV over 10 min (21.7%) and below average number (42.5%)

168 indicated that the effect of timing in administration of Tranexamic acid was very  
169 significant (Table 5). Indication of 1---3 hours after child birth as the best range of time to  
170 administer Tranexamic acid for optimal result was very poor (14.5%) while the indication  
171 that the use of tranexamic acid in women with contraindication to antifibrinolytic therapy  
172 not being a part of current routine care for Postpartum Haemorrhage treatment was  
173 about average (52.2%). Majority however perceived that Tranexamic acid should be  
174 considered as part of the standard postpartum haemorrhage treatment package (71.5%).

175

### 176 **Barriers against use of Tranexamic acid for postpartum hemorrhage**

177 There were various barriers identified as constraints to the use of Tranexamic acid by  
178 healthcare workers to manage Postpartum Haemorrhage. The most common barrier was  
179 ignorance about the latest recommendation by the WHO on the use of Tranexamic acid.  
180 The next most common barrier was preference for substitute drugs for the condition  
181 (Figure 1).

182

### 183 **Relationship profession, institution, knowledge of TXA for postpartum hemorrhage**

184 There was no significant relationship observed between profession and Institution with  
185 knowledge of the use of Tranexamic acid for postpartum hemorrhage (Table 6)  
186 Proportion of those with good knowledge between the different professions was  
187 comparable: medical doctor (22.4%), pharmacist (27.9%) and nurse/midwife (20.5%);  
188 and likewise between institutions: UNTH (25.5%) and ESUTH (20.0%).

189

### 190 **Relationship of profession, institution, use of TXA for postpartum hemorrhage**



191 The use of Tranexamic acid for postpartum hemorrhage had significant relationship with  
192 both profession ( $p < .001$ ) and institution ( $p < .001$ ). Specifically, for profession, use of  
193 Tranexamic acid for postpartum hemorrhage was highest among pharmacists (61.8%)  
194 followed by medical doctors (44.0%) and the least was nurses/midwives (18.4%). More  
195 than half of the respondents from the UNTH (59.7%) used Tranexamic acid for  
196 postpartum hemorrhage unlike their counterparts in ESUTH (Table 7). In addition, there  
197 was a significant relationship between knowledge about the use of Tranexamic acid for  
198 postpartum hemorrhage and the use of it ( $p < .001$ ). Those with good knowledge on the  
199 use (66.7%) were associated with the actual use far more than those with poor  
200 knowledge (37.2%). More specifically, the odds of use of Tranexamic acid for postpartum  
201 hemorrhage was 3.4 times [95% C.I- 1.67-6.84] higher among those with good  
202 knowledge than those with poor knowledge.

203

## 204 **DISCUSSION**

205 This study has the strength of being the first because there are no studies in published  
206 literature assessing the knowledge and use of Tranexamic acid for postpartum  
207 hemorrhage among health care providers. Majority of the surveyed health providers  
208 failed the definition of postpartum hemorrhage which is generally defined as blood loss of  
209 500 ml and above after delivery through the vagina or blood loss of 1000 ml and above  
210 after delivery through cesarean section <sup>15</sup>. Approximately, half of the respondents in this  
211 current study understood the mechanism of action of Tranexamic acid. Medical or health  
212 care professionals in gynecology should have the knowledge of the mechanism of action  
213 of Tranexamic acid. The mechanism of action of Tranexamic acid as explained by Cai  
214 and colleagues is brought about through blocking the binding site for lysine on

215 plasminogen molecules thereby preventing the association of plasminogen with already  
216 formed plasmin and fibrin thus stopping rapid fibrinolysis of the formed fibrin mesh <sup>16</sup>

217  
218 There was poor use of Tranexamic acid and even among providers that use it, majority  
219 didn't know the recommended dose. An average proportion of the respondents were not  
220 sure of the appropriate dose of Tranexamic acid for the management of postpartum  
221 hemorrhage. In fact a minimal percentage of them got the correct dose which was a  
222 loading dose of 1 g (100 mg/mL) intravenously given at a rate of 1 mL/min <sup>3</sup> Tranexamic  
223 acid is one of the evidence-based approaches to reducing the incidence of adverse  
224 maternal outcomes associated with PPH. Other equally important approaches are  
225 prompt blood transfusion as well as active management of the third stage of labor <sup>17</sup>. The  
226 proportion of the respondents who agreed that timing plays a significant role in the  
227 administration of Tranexamic acid were almost the same proportion as those who  
228 thought that immediate administration and 1-3 hours after birth put together. Those who  
229 thought that the administration of Tranexamic acid immediately after child birth was the  
230 best time range of Tranexamic acid for optimum outcome were much more than those  
231 who got the correct time range which was between 1 to 3 hours after child birth. In reality,  
232 the time range with evident advantage was between 1-3 hours. In fact it was observed  
233 that this timely administration significantly reduced the risk of mortality due to bleeding as  
234 well as the reliance on laparotomy for bleeding control <sup>3</sup>. The poor knowledge and use  
235 observed in this current study could be attributed to not being updated on current  
236 guidelines and also lack of advocacy and training of health professional. Importance of  
237 training can never be over emphasized regarding emergency obstetrics response. There

238 is evidence that trainings aimed to improve clinical knowledge and skills with respect to  
239 the risk factors of postpartum hemorrhage prevents maternal morbidity and mortality<sup>17</sup>.

240  
241 Few respondents have recommended, dispensed or administered and actually used it in  
242 practice despite recognizing it as a lifesaving intervention that should be made available  
243 for the management of Tranexamic acid in Obstetrics practice. They were more likely to  
244 use it for other cases of bleeding than postpartum hemorrhage. It shows that there is still  
245 room for greater awareness to be created for the use of Tranexamic acid in postpartum  
246 hemorrhage management. Possible avenues include clinical meetings and continuous  
247 professional development sessions. This suboptimal practice could also be as a result of  
248 not being updated on the most current guideline. Perhaps other reasons could be related  
249 to the barriers against its use as observed in this current study. Some of the perceived  
250 barriers were ignorance of the latest recommendation, preference to other uterotonics,  
251 high cost of drug, and fear of thromboembolic event and drug scarcity.

252 One of the barriers identified in this study against the optimal use of Tranexamic acid for  
253 the management of postpartum hemorrhage was high cost of the former. It is important  
254 to highlight here some of the outcomes from cost-effectiveness studies done on the use  
255 of Tranexamic acid for postpartum hemorrhage. Li Bernadette and colleagues calculated  
256 the incremental cost-effectiveness ratios (ICER) of treating postpartum hemorrhage  
257 within 3 hours of giving birth with or without Tranexamic acid. Results generated were  
258 optimistic. Despite the possibility of increasing the relative risk of death due to bleeding  
259 while on Tranexamic acid to the upper bound of 0.91, the ICER was \$ 692 per Quality-  
260 adjusted life-Years (QALY). In addition, if the discount rate was applied as high as 10%,  
261 the ICER (\$ 507 per QALY) was still within the threshold range of Nigeria (\$ 446 - \$ 2880

262 per QALY) i.e. within the cost-effective range. In summary, at the lower threshold range  
263 (\$ 446 per QALY) the probability that Tranexamic acid is cost-effective is 93% <sup>18</sup> This is  
264 comparable with the results from a more recent study in a developed country <sup>6</sup>

265

## 266 **CONCLUSION**

267 The findings show that there is poor knowledge about the use of WHO recommended  
268 Tranexamic acid for postpartum hemorrhage among different cadres of healthcare  
269 workers. The uptake of the recommendation among health workers was rather low and  
270 seriously affecting its use. Most health providers have a poor awareness of the  
271 recommendation which led to a poor practice and use.

272

## 273 **RECOMMENDATIONS**

274 A major limitation of this study was the cross sectional design adopted. Therefore there is  
275 need for prospective studies which would provide a more robust evidence on the cost  
276 effectiveness of Tranexamic acid for postpartum hemorrhage. This will provide basis for  
277 the advocacy by policy makers targeting professionals and updating them on current best  
278 practices and also alleviating their fears.

279

280 The authors declare no conflict of interest

281 There was no external funding for this study

## 282 **Authors' contribution**

283 **Conceptualization:** Kingsley Ekwuazi, Ogochukwu Onwujekwe, Adaobi  
284 Mosanya & Chukwuemeka Iyoke

285 **Data Curation:** Ogochukwu Onwujekwe, Adaobi Uchenna Mosanya &  
286 Chukwuemeka Iyoke  
287 **Formal analysis:** Ogochukwu Onwujekwe & Adaobi Uchenna Mosanya  
288 **Methodology:** Kingsley Ekwuazi & Ogochukwu Onwujekwe  
289 **Supervision:** Chukwuemeka Iyoke  
290 **Writing – original draft:** Ogochukwu Onwujekwe, Adaobi Uchenna Mosanya,  
291 Kingsley Ekwuazi & Chukwuemeka Iyoke  
292 **Writing – review & editing:** Ogochukwu Onwujekwe, Adaobi Uchenna Mosanya,  
293 Kingsley Ekwuazi & Chukwuemeka Iyoke  
294

## 295 REFERENCES

- 296 1. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: A WHO  
297 systematic analysis. *Lancet Glob. Health.* 2014;2(6). doi:10.1016/S2214-  
298 109X(14)70227-X
- 299 2. Piane GM. Maternal Mortality in Nigeria: A Literature Review. *World Med. Health*  
300 *Policy.* 2019;11(1):83-94. doi:10.1002/wmh3.291
- 301 3. Shakur H, Roberts I, Fawole B, et al. Effect of early tranexamic acid administration  
302 on mortality, hysterectomy, and other morbidities in women with post-partum  
303 haemorrhage (WOMAN): an international, randomised, double-blind, placebo-  
304 controlled trial. *Lancet.* 2017;389(10084):2105-2116. doi:10.1016/S0140-  
305 6736(17)30638-4
- 306 4. World Health Organization. Updated WHO Recommendation on Tranexamic Acid  
307 for the Treatment of Postpartum Haemorrhage: Highlights and Key Messages from

- 308 the World Health Organization's 2017 Global Recommendation. 2017;(October):5.
- 309 5. Sudhof LS, Shainker SA, Einerson BD. Tranexamic acid in the routine treatment of  
310 postpartum hemorrhage in the United States: a cost-effectiveness analysis. *Am. J.*  
311 *Obstet. Gynecol.* 2019;221(3):275.e1-275.e12. doi:10.1016/j.ajog.2019.06.030
- 312 6. Howard DC, Jones AE, Skeith A, Lai J, D'Souza R, Caughey AB. Tranexamic acid  
313 for the treatment of postpartum hemorrhage: a cost-effectiveness analysis. *Am. J.*  
314 *Obstet. Gynecol MFM.* 2022;4(3):100588. doi:10.1016/j.ajogmf.2022.100588
- 315 7. Modir H, Moshiri E, Naseri N, Faraji F, Almasi-Hashiani A. A randomized parallel  
316 design trial of the efficacy and safety of tranexamic acid, dexmedetomidine and  
317 nitroglycerin in controlling intraoperative bleeding and improving surgical field  
318 quality during septorhinoplasty under general anesthesia. *Med. Gas Res.*  
319 2021;11(4):131-137. doi:10.4103/2045-9912.318857
- 320 8. Wong J, George RB, Hanley CM, Saliba C, Yee DA, Jerath A. Tranexamic acid:  
321 current use in obstetrics, major orthopedic, and trauma surgery. *Can J Anaesth*  
322 2021;68(6):894-917. doi:10.1007/s12630-021-01967-7
- 323 9. Franchini M, Mengoli C, Cruciani M, et al. Safety and efficacy of tranexamic acid  
324 for prevention of obstetric haemorrhage: An updated systematic review and meta-  
325 analysis. *Blood Transfus.* 2018;16(4):329-337. doi:10.2450/2018.0026-18
- 326 10. Eyeberu A, Getachew T, Amare G, et al. Use of tranexamic acid in decreasing  
327 blood loss during and after delivery among women in Africa: a systematic review  
328 and meta-analysis. *Arch. Gynecol. Obstet.* 2022;(0123456789).  
329 doi:10.1007/s00404-022-06845-1

- 330 11. Wang K, Santiago R. Tranexamic acid – A narrative review for the emergency  
331 medicine clinician. *Am. J. Emerg. Med.* 2022;56:33-44.  
332 doi:10.1016/j.ajem.2022.03.027
- 333 12. Van Houwe M, Roofthoof E, Van de Velde M. The role of tranexamic acid in  
334 obstetric hemorrhage: a narrative review. *Acta Anaesthesiol. Belg.* 2022;73(2):103-  
335 108. doi:10.56126/73.2.12
- 336 13. Bouthors AS, Gilliot S, Sentilhes L, et al. The role of tranexamic acid in the  
337 management of postpartum haemorrhage. *Best Pract. Res. Clin. Anaesthesiol.*  
338 2022;36:411-426. doi:10.1016/j.bpa.2022.08.004
- 339 14. Bellos I, Pergialiotis V. Tranexamic acid for the prevention of postpartum  
340 hemorrhage in women undergoing cesarean delivery: an updated meta-analysis.  
341 *Am. J. Obstet. Gynecol.* 2022;226(4):510-523.e22. doi:10.1016/j.ajog.2021.09.025
- 342 15. Smith JR. Medscape. Postpartum Hemorrhage.  
343 <https://emedicine.medscape.com/article/275038-print>. Published 2022. Accessed  
344 January 16, 2023.
- 345 16. Cai J, Ribkoff J, Olson S, et al. The many roles of tranexamic acid: An overview of  
346 the clinical indications for TXA in medical and surgical patients. *Eur. J. Haematol.*  
347 2020;104(2):79-87. doi:10.1111/ejh.13348
- 348 17. Cooper N, O'Brien S, Siassakos D. Training health workers to prevent and manage  
349 post-partum haemorrhage (PPH). *Best Pract Res Clin Obstet Gynaecol*  
350 2019;61(November 2019):121-129. doi:10.1016/j.bpobgyn.2019.05.008

351 18. Li B, Miners A, Shakur H, Roberts I. Tranexamic acid for treatment of women with  
352 post-partum haemorrhage in Nigeria and Pakistan: a cost-effectiveness analysis of  
353 data from the WOMAN trial. *Lancet Glob. Health* 2018;6(2):e222-e228.  
354 doi:10.1016/S2214-109X(17)30467-9

355

356

357

358

359

360

361

362

363

364

365

366

367

368



369 **Table 1: Demographic Characteristics of the Health Professionals**

		Frequency	Percent
<b>Age</b>	<30	66	31.9
	30-39	96	46.4
	40-49	36	17.4
	50-59	8	3.9
	≥ 60	1	0.5
<b>Sex</b>	Male	89	43.0
	Female	118	57.0
<b>Profession</b>	Medical doctor	107	51.7
	Pharmacist	61	29.5
	Nurse/midwife	39	18.8
<b>Medical Doctors' cadre (n = 107)</b>	House officer	52	48.6
	Registrar	44	41.1
	Senior registrar	5	4.7
	Consultant	6	5.6
<b>Cadre of Pharmacists (n = 61)</b>	Intern	18	29.5
	Senior pharmacist	12	19.7
	Principal pharmacist	12	19.7
	Chief pharmacist	8	13.1
	Assistant director	9	14.8
	Deputy director	2	3.3
<b>Nurses' cadre (n = 39)</b>	Intern	2	5.1
	Staff nurse/midwife	22	56.4
	Senior nursing officer	8	20.5
	PNO	1	2.6
	Matron	3	7.7
	CNO	1	2.6
	Senior matron	2	5.1
<b>Highest level of education</b>	Diploma	13	6.3
	Bachelors/1st degree	140	67.6
	Master's degree	24	11.6
	Professional fellowship	22	10.6
	No response	8	3.9
<b>Years of practice in profession</b>	< 5	82	39.6
	5-10	70	33.8
	11-15	27	13.0
	16-20	13	6.3
	21-25	3	1.4
	26-30	3	1.4
	> 30	3	1.4
	No response	6	2.9

370

371 **Table 2: Knowledge about use of tranexamic acid for postpartum haemorrhage**

	Yes	No	Don't know	Chi-Square	P-value
Postpartum hemorrhage is defined as blood loss of 1000ml or more within 24 hours after birth	157(75.8)	40(19.3) <sup>a</sup>	10(4.8)	174.870	<.001
Majority of PPH associated deaths could be avoided by the use of prophylactic uterotonics during the third stage of labour	<sup>a</sup> 177(85.5)	5(2.4)	25(12.1)	256.464	<.001
The Guideline Development Group meeting on the prevention and treatment of PPH in March 2012 concluded there was no direct evidence of the effectiveness and safety of TXA for PPH	29(14.0) <sup>a</sup>	43(20.8)	135(65.2)	96.116	<.001
TXA is a synthetic lysine analog trans-4 aminoethylcyclohexanecarboxylic acid	<sup>a</sup> 104(50.2)	3(1.4)	100(48.3)	94.812	<.001
The mechanism of action of TXA is by binding to plasminogen and thereby blocking activation to plasmin leading to inhibition of fibrinolysis and fibrinogenolysis	95(45.9) <sup>a</sup>	32(15.5)	80(38.6)	31.391	<.001
The April 2017 world maternal anti-fibrinolytic (WOMAN) trial supersedes the March 2012 trial	52(25.1) <sup>a</sup>	3(1.4)	152(73.4)	167.159	<.001
The woman trial for PPH concluded on oral and intravenous administration of TXA for PPH	83(40.1)	11(5.3) <sup>a</sup>	113(54.6)	79.652	<.001
PPH is a leading cause of maternal mortality with about one quarter of all maternal deaths associated with it in low income countries	<sup>a</sup> 184(88.9)	3(1.4)	20(9.7)	289.594	<.001

<sup>a</sup>**indicates the right responses- correct knowledge or use**

372 **Table 3: The categorized knowledge score about use of TXA for PPH**

		Frequency	Percent	Chi-Square	P-Value
Good	<i>(Knowledge score &gt; 50%)</i>	49	23.7	57.40	<.001
Poor	<i>(Knowledge score ≤ 50%)</i>	158	76.3		

373

374

375

376 **Table 4: Provider's use of TXA for PPH**

	Yes	No	Don't know	Chi-Square	P-value
TXA should be used in all cases of PPH regardless of if bleeding is due to genital tract trauma or other causes	58(28.0) <sup>a</sup>	86(41.5)	63(30.4)	6.46	.039
Have you recommended/dispensed TXA for the management or prevention of PPH?	62(30.0) <sup>a</sup>	129(62.3)	16(7.7)	93.59	<.001
Do you use TXA in all cases of PPH regardless of if bleeding is due to genital tract trauma or other causes?	34(16.4) <sup>a</sup>	160(77.3)	13(6.3)	183.22	<.001
Do you recognize TXA as a life-saving intervention for managing PPH in obstetrics practice?	<sup>a</sup> 155(74.9)	38(18.4)	14(6.8)	164.96	<.001
Have you used TXA for other cases of bleeding or haemorrhage other than for PPH?	74(35.7) <sup>a</sup>	102(49.3)	31(15.0)	37.07	<.001

<sup>a</sup>*indicates the right responses- correct knowledge or use*

377

378

379 **Table 5: Use of tranexamic acid for postpartum haemorrhage**

	Frequency	Percent	Chi-Square	P-Value
<b>Do you use/dispense tranexamic acid for the management of post-partum haemorrhage in your facility?</b>			2.74	.098
- Yes <sup>a</sup>	85	41.1		
- No	108	52.2		
- <i>No response</i>	14	6.8		
<b>Recommended dosage regimen used for tranexamic acid in PPH treatment?</b>			239.06	<.001
- 2g (200mg/ml) IV over 10 min	19	9.2		
- 3g (300mg/ml) IV over 20 min	14	6.8		
- 1g (100mg/ml) IV over 10 min <sup>a</sup>	45	21.7		
- 4g (400mg/ml) IV over 10 min	3	1.4		
- Don't know	126	55.6		
<b>What is the effect of timing in the administration of tranexamic acid for post-partum haemorrhage</b>			71.51	<.001
- Not significant	4	1.9		
- Very significant <sup>a</sup>	88	42.5		
- Not sure	53	25.6		
- Don't know	62	28.5		
<b>What is the best range of time to administer tranexamic acid for optimal result</b>			256.10	<.001
- Immediately after child birth	58	28.0		
- 1-3 hours after child birth <sup>a</sup>	30	14.5		
- 4-6 hours after child birth	6	2.9		
- 7-10 hours after child birth	2	1.0		
- > 10 hours after child birth	3	1.4		
- Don't know	108	52.2		
<b>Which of these is not a part of the current routine care for PPH treatment?</b>			138.34	<.001
- Fluid replacement	20	9.7		
- Surgical interventions	24	11.6		
- Use of tranexamic acid in women with contraindication to antifibrinolytic therapy <sup>a</sup>	108	52.2		
- Monitoring vital signs	36	17.4		
- <i>No response</i>	19	9.2		
<b>Tranexamic acid should be considered as part of the standard PPH treatment package?</b>			57.87	<.001
- Strongly agree <sup>a</sup>	73	35.3		
- Agree <sup>a</sup>	75	36.2		
- Disagree	7	3.4		
- Don't know	52	25.1		

<sup>a</sup>indicates the right responses- correct knowledge or use

381 **Table 6: Relationship between Profession, Institution and Knowledge of TXA for**  
 382 **PPH**

		Knowledge on Use of TXA for PPH			Chi-Square	p-value
		Good (n = 49)	Poor (n = 158)	Total (n = 207)		
Profession	Medical doctor	24(22.4)	83(77.6)	107	.901	.637
	Pharmacist	17(27.9)	44(72.1)	61		
	Nurse/midwife	8(20.5)	31(79.5)	39		
Institution	UNTH	35(25.5)	102(74.5)	137	.789	.374
	ESUTH	14(20.0)	56(80.0)	70		

383

384

385

386

387 **Table 7: Relationship between Profession, Institution and Use of TXA for PPH**

		Use of TXA for Postpartum hemorrhage			Chi-Square	p-value
		Yes (n = 85)	No (n = 108)	Total (n = 207)		
Profession	Medical doctor	44(44.0)	56(56.0)	100	17.174	<.001
	Pharmacist	34(61.8)	21(38.2)	55		
	Nurse/midwife	7(18.4)	31(81.6)	38		
Institution	UNTH	74(59.7)	50(40.3)	124	34.407	<.001
	ESUTH	11(15.9)	58(84.1)	69		

388